V

Vaxxinity, Inc.

0001851657

Vaxxinity, Inc. focuses on developing vaccine platforms for chronic diseases. The company's primary focus shifted away from public reporting and ongoing financial disclosures after ceasing to file reports with the SEC. Information is limited due to the company going dark.

65
Moderat Pålitelig
Tillitsscore

Offisielt Register

MVA Nummer
862083865
Adresse
505 ODYSSEY WAY, EXPLORATION PARK, FL 32953
Bransjekoder
Pharmaceutical Preparations, 2834

AI Kvalitetsanalyse

Bransje
Biotechnology
SSL/HTTPS
Sikker
Profesjonell E-post
Nei

Tillitsscore Detaljer

Register Verifisert35/35
Kvalitetsscore30/60
Nyhetsanalyse0/5

Snarveier

Nettside Høydepunkter

Sist oppdatert: 1/2/2026

🌟 Lignende Pålitelige Bedrifter

Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. logo
89/100 · Meget Pålitelig

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. They have a fully integrated team dedicated to research, development, and cell manufacturing. Their goal is to deliver "off-the-shelf" CAR T cell candidates faster and more reliably.

210 EAST GRAND AVENUE, USA
Se profil

Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc. logo
71/100 · Pålitelig

Spyre Therapeutics is engineering next-generation antibodies for prolonged activity, focused on inflammatory bowel disease (IBD) and other immune-mediated diseases. They are developing monotherapies and combination therapies designed for uncompromising efficacy and convenience. Their pipeline targets validated mechanisms with the potential to treat several gastrointestinal and rheumatic conditions. The company is committed to improving the lives of patients through innovative treatment options.

221 CRESCENT STREET, USA
Se profil

Prime Medicine, Inc.

Prime Medicine, Inc. logo
86/100 · Meget Pålitelig

Prime Medicine is a biotechnology company focused on developing gene therapies using Prime Editing technology. They aim to cure genetic diseases by precisely editing DNA. Developed at the Broad Institute, Prime Editing has the potential to address a wide range of diseases and overcome limitations of existing gene editing approaches.

60 FIRST ST., USA
Se profil